Filing Details
- Accession Number:
- 0001104659-25-054260
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-05-29 16:15:16
- Reporting Period:
- 2025-05-27
- Filing Date:
- 2025-05-29
- Accepted Time:
- 2025-05-29 16:15:16
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1657312 | Verona Pharma Plc | VRNA | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1627642 | David Zaccardelli | 3 More London Riverside London X0 SE1 2RE | President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Disposition | 2025-05-27 | 33,600 | $9.53 | 13,956,568 | No | 4 | S | Direct | |
| Ordinary Shares | Disposition | 2025-05-28 | 157,704 | $9.30 | 13,798,864 | No | 4 | S | Direct | |
| Ordinary Shares | Disposition | 2025-05-29 | 208,696 | $9.33 | 13,590,168 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
- The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted on January 29, 2025.
- The price reported represents a weighted average price of the ADSs divided by eight (8). The securities were sold in multiple transactions at prices ranging from $9.50 to $9.595 per Ordinary Share, inclusive (or $76.00 to $76.76 per ADS, inclusive). The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- The price reported represents a weighted average price of the ADSs divided by eight (8). The securities were sold in multiple transactions at prices ranging from $9.25 to $9.4513 per Ordinary Share, inclusive (or $74.00 to $75.61 per ADS, inclusive). The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- The price reported represents a weighted average price of the ADSs divided by eight (8). The securities were sold in multiple transactions at prices ranging from $9.25 to $9.385 per Ordinary Share, inclusive (or $74.00 to $75.08 per ADS, inclusive). The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- Consists of (i) 2,450,000 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 306,250 ADSs); and (ii) 11,140,168 Ordinary Shares underlying 1,392,521 ADSs.
Billionaire Hedge Funds
